Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies— a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)

In treatment-naive and treatment-experienced Asian patients with chronic HCV genotype 1–6 infection with (VOYAGE-2) and without (VOYAGE-1) cirrhosis, glecaprevir–pibrentasvir showed high efficacy and acceptable safety; responses were less common in those with genotype 3b.


Lancet Gastroenterology and Hepatology